论文部分内容阅读
目的研究与探讨肝动脉及门静脉双介入化疗栓塞对治疗原发性中晚期肝癌的可行性及临床疗效。方法86例中晚期肝癌患者分为A、B两组,A组应用肝动脉与门静脉双介入灌注化疗及栓塞(TACE+SPVE)方法治疗患者43例,B组单纯采用肝动脉灌注化疗及栓塞(TACE)方法治疗患者43例。结果A、B两组的近期有效率分别为86.1%和69.8%,治疗后获得二期手术切除率两组分别为16.2%和4.7%,差异有显著性意义(P<0.05)。治疗后0.5、1、2年生存率,A组为90.6%、62.8%、53.5%,B组为72.1%、48.8%、39.5%,两组间差异有显著性意义(P<0.05)。并发症方面两组之间无显著性差异。结论应用肝动脉与门静脉双介入治疗中晚期原发性肝癌,优于单纯肝动脉介入治疗的效果。
Objective To study and investigate the feasibility and clinical efficacy of double interventional chemotherapy and embolization of hepatic artery and portal vein in the treatment of primary advanced liver cancer. Methods A total of 86 patients with advanced hepatocellular carcinoma (HCC) were divided into two groups: group A and group B, 43 patients were treated with transcatheter arterial chemoembolization (TACE + SPVE) and group A with hepatic arterial infusion chemotherapy and embolism TACE) treatment of 43 patients. Results The immediate effective rates of group A and group B were 86.1% and 69.8% respectively, and the rates of the second stage resection after operation were 16.2% and 4.7%, respectively. There was significant difference between the two groups (P <0.05). The survival rates at 0, 5, 1 and 2 years after treatment were 90.6%, 62.8% and 53.5% in group A and 72.1%, 48.8% and 39.5% in group B, respectively. There was significant difference between the two groups (P <0.05). There was no significant difference between the two groups in terms of complications. Conclusion Double hepatic artery and portal vein intervention in the treatment of advanced primary hepatocellular carcinoma is superior to interventional hepatic artery alone.